Selective TGF-β Superfamily Therapeutics
About BYOMass
BYOMass is a preclinical pharmaceutical company developing novel biologic and small molecule drugs to modulate specific members of the TGF-β superfamily, for the treatment of orphan and common diseases of high unmet medical need. Our mission is to:
- Harness human biology
- Target causative mechanisms
- Deliver novel therapeutics
- Transform patient lives
TGF-β Superfamily in Disease
The TGF-β superfamily of secreted factors includes more than 30 members, including transforming growth factors (TGFs), growth differentiation factors (GDFs), activins, inhibins, nodal, lefty, and bone morphogenetic proteins (BMPs). These proteins are master regulators of a wide range of physiological processes including tissue morphogenesis, tissue repair, hematopoiesis, immunoregulation and reproductive function. Dysregulation of individual proteins cause multiple diseases and disorders, including inflammation, catabolism, fibrosis, appetite loss, and carcinogenesis.
Inhibiting TGF-β directly or blocking receptors with multiple signaling ligands is not an attractive therapeutic approach due to safety concerns. Selectively targeting specific members and pathways within the superfamily has the potential to be a meaningful class of therapeutics within oncology, inflammatory/immune, fibrotic, and metabolic diseases.
At BYOMass, we are delivering a new era of selective TGF-β superfamily therapeutics. We have a home-grown, pathway-driven pipeline of novel biologics and first-in-class small molecules that offer safe and transformative efficacy for orphan and common diseases of high unmet medical need.
Building a TGF-β Superfamily Pathway Pipeline on
Precision Medicine Principles
BYOMass is pioneering a precision medicine approach to treat patients with high unmet medical need where specific TGF-β superfamily members play a major role in their disease. Our approach to building a therapeutic pipeline follows these principles:
Efficacy
Harnessing human biology and causal mechanisms of disease for transformative efficacy
Safety
Avoiding known toxicities associated with directly blocking TGF-β or subfamily receptors
Preclinical to Clinical Translation
Utilizing plasma biomarkers to stratify patients and build confidence in human dose (PK/PD)
Modality
Developing novel biologics and small molecules
Clinical Candidates Built to Survive
Establishing conservative human dose predictions with high confidence in PK/PD and optimal therapeutic index to ensure ability to fully test a first-in-class mechanism in patients
Clinical Development Flexibility & Path
Building innovative clinical development plans to deliver an early sign of efficacy in Phase 1 in an accelerated timeframe and capital-efficient manner. Designing programs for rapid ‘orphan drug’, specialty-focused, and general medicine indications of high unmet medical need to improve patient lives
BYOMass Leadership
We are a highly experienced drug discovery and development team from large pharma with the cost efficiency of an agile start-up. Our leadership team has a successful track record of delivering novel therapeutics across multiple indications.